ApniCure

The company's core business centered on the development and commercialization of home-use medical devices for sleep-related disorders. ApniCure's flagship product was the Winx™ Sleep Therapy System, designed as an alternative for patients with mild, moderate, and severe OSA who found CPAP machines uncomfortable or inconvenient. The business model initially focused on distributing the Winx system through sleep labs, but later shifted to a direct-to-consumer approach combined with telehealth services, allowing patients to consult with sleep therapists via online video appointments. This strategy aimed to reach individuals who had given up on CPAP therapy altogether.

The Winx system utilized a proprietary technology called Oral Pressure Therapy (OPT). Unlike CPAP machines that use forced air, the Winx system created a light oral vacuum. The device consisted of a quiet, bedside console connected by a slim tube to a soft, flexible mouthpiece. This mouthpiece would gently pull the soft palate forward and stabilize the tongue, thereby keeping the airway open for natural breathing during sleep. Key features included the mask-free design, quiet operation, and slim tubing that allowed for greater freedom of movement during sleep. The system also had a data management feature to track patient usage on an SD card. After successful clinical trials, the Winx system received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2012, allowing it to be marketed in the United States. Despite its novel approach and initial market entry, ApniCure went out of business in late 2017, and the Winx system is no longer available.